Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f4bbf2628367b8bb62a96259e0f4232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90e6b9f9184ac1ddf060d92cb23e5cb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c547417cefc1a20b3a9c5f7f5bfbc73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f2cf31ab0a91091292130fb05549791 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
filingDate |
2010-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81819401943956a1fc219a6dda3103fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12e0783d5e56b35be770fb81c8411b33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4ad68fac1f3de5eecdc66e620b1d290 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b120fb20d3a28dd11b92d32d77587102 |
publicationDate |
2013-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8362014-B2 |
titleOfInvention |
ABT-263 crystalline forms |
abstract |
ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014160071-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285159-B2 |
priorityDate |
2009-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |